Systematic approaches to smoking cessation in the cardiac setting

Current Opinion in Cardiology

Volumn 26, Issue 5, 2011, Pages 443-448

  Reid, Robert D ^a   Mullen, Kerri A ^a   Pipe, Andrew L ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

coronary heart disease; counseling; knowledge translation; pharmacotherapy; relapse prevention; smoking cessation

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINE; NICOTINE GUM; NICOTINE PATCH; PLACEBO; VARENICLINE;

CARDIAC PATIENT; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; MASS SCREENING; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RELAPSE; REVIEW; RISK REDUCTION; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; VASCULAR ENDOTHELIUM;

CORONARY DISEASE; HUMANS; SMOKING CESSATION;

EID: 80051800852     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283497499     Document Type: Review

References (33)

1. Bullen C. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. Expert Rev Cardiovasc Ther 2008; 6:883-895.
2. Burns DM. Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis 2003; 46:11-29.
3. Benowitz NL. Pharmacology of nicotine: Addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009; 49: 57-71.
4. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004; CD003041.
5. Mohiuddin SM, Mooss AN, Hunter CB, et al. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 2007; 131:446-452.
6. Reid RD, Pipe AL, Quinlan B. Promoting smoking cessation during hospitalization for coronary artery disease. Can J Cardiol 2006; 22:775-780.
7. Reid R, Pipe A, Higginson L, et al. Stepped care approach to smoking cessation in patients hospitalized for coronary artery disease. J Cardiopulm Rehabil 2003; 23:176-182.
8. Reid RD, Pipe AL, Quinlan B, Oda J. Interactive voice response telephony to promote smoking cessation in patients with heart disease: A pilot study. Patient Educ Couns 2007; 66:319-326.
9. Pipe AL, Papadakis S, Reid RD. The role of smoking cessation in the prevention of coronary artery disease. Curr Atheroscler Rep 2010; 12:145-150.
10. Reid RD, Quinlan B, Riley DL, Pipe AL. Smoking cessation: Lessons learned from clinical trial evidence. Curr Opin Cardiol 2007; 22:280-285.
11. Pipe AL, Eisenberg MJ, Gupta A, et al. Smoking cessation and the cardiovascular specialist: Canadian Cardiovascular Society position paper. Can J Cardiol 2011; 27:132-137. This statement from the Canadian Cardiovascular Society provides recommendations for cardiovascular specialists' management of tobacco addiction and smoking cessation.
12. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA 2003; 290:86-97.
13. Frey P, Waters DD, DeMicco DA, et al. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials). Am J Cardiol 2010; 107:145-150.
14. Shah AM, Pfeffer MA, Hartley LH, et al. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol 2010; 106:911-916.
15. Johnson HM, Gossett LK, Piper ME, et al. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2010; 55:1988-1995.
16. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2008.
17. Agboola S, McNeill A, Coleman T, Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010; 105:1362-1380. This systematic review examines the efficacy of relapse prevention interventions for abstinent smokers.
18. Reda AA, Kaper J, Fikrelter H, et al. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev 2009; CD004305.
19. McEwen A, Hajek P, McRobbie H, West R. Manual of smoking cessation: A guide for counsellors and practitioners. Oxford: Blackwell Publishing; 2006.
20. Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: A systematic review. Arch Intern Med 2008; 168:1950-1960.
21. Barth J, Critchley J, Bengel J. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev 2008; CD006886.
22. Wolfenden L, Campbell E, Walsh R, Wiggers J. Smoking cessation interventions for in-patients: A selective review with recommendations for hospitalbased health professionals. Drug Alcohol Rev 2003; 22:437-452.
23. Reid RD, Mullen KA, Slovinec D'Angelo ME, et al. Smoking cessation for hospitalized smokers: An evaluation of the 'Ottawa Model'. Nicotine Tob Res 2010; 12:11-18. This study demonstrates the impact of implementing the Ottawa Model for Smoking Cessation in nine hospitals in eastern Ontario, which led to significantly higher long-term cessation rates in smokers.
24. Balmford J, Borland R, Hammond D, Cummings KM. Adherence to and reasons for premature discontinuation from stop-smoking medications: Data from the ITC Four-Country Survey. Nicotine Tob Res 2011; 13:94-102.
25. Hubbard R, Lewis S, Smith C, et al. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control 2005; 14:416-421.
26. Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis 2003; 45:429-441.
27. Meine TJ, Patel MR, Washam JB, et al. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005; 95:976-978.
28. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82-e292.
29. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: A multicentre, randomised study. Eur Heart J 2003; 24:946-955.
30. Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med 2006; 119:1080-1087.
31. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 2010; 121:221-229. This study is the first to report the efficacy and safety of varenicline for smoking cessation in patients with stable cardiovascular disease; the study also observes the occurrence of psychiatric adverse events and assesses the frequency of these symptoms.
32. Smeeth L, Fowler G. Nicotine replacement therapy for a healthier nation. Nicotine replacement is cost effective and should be prescribable on the NHS. BMJ 1998; 317:1266-1267.
33. Tran K, Asakawa K, Cimon K, et al. Pharmacologic-based strategies forsmoking cessation: Clinical and cost-effectiveness analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2010 Contract No. (Technology Report; no. 130).